ReviewVascular health and risk management2022
Kawasaki Disease: Pathology, Risks, and Management.
Review in Vascular health and risk management, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- The characteristics of the gut microbiota in patients with Kawasaki disease: a systematic review.Frontiers in microbiology · 2025Pooled it
- Paeoniflorin Alleviates Coronary Artery Lesions in Kawasaki Disease by Activating NRF2 Pathway and Inhibiting CYP2E1 Expression.Cardiovascular drugs and therapy · 2026Article
- Early post-IVIG serum IgG concentration does not explain IVIG non-response in Kawasaki disease.European journal of pediatrics · 2026Article
- The expression of C-reactive protein, erythrocyte sedimentation rate, and procalcitonin in children with Kawasaki disease and their correlation with coronary artery ectasia.BMC pediatrics · 2026Article
- Comprehensive machine learning for identifying platelet-associated diagnostic biomarkers and immune landscape in Kawasaki disease.Translational pediatrics · 2026Article
- Resveratrol ameliorates myocardial injury and inflammatory response and cell apoptosis in Kawasaki disease rats by activating the Nrf2/HO-1 pathway.Journal of cardiothoracic surgery · 2026Article
- Application of 3T contrast-enhanced Dixon water-fat separation coronary magnetic resonance angiography with artificial intelligence-assisted compressed sensing on coronary artery aneurysm in children with Kawasaki disease.Translational pediatrics · 2026Article
- AUDA suppresses apoptosis of HCAECs induced by TNF and serum of Kawasaki disease patients by inhibiting endoplasmic reticulum stress.Open life sciences · 2026Article
- The correlation and auxiliary diagnostic value of gut microbiota and serological indicators with Kawasaki disease complicated by coronary artery lesions.Frontiers in cellular and infection microbiology · 2026Article
- An integrated and interpretable machine learning framework for Kawasaki disease diagnosis and risk prediction.Translational pediatrics · 2025Article
- Clinical value of combined detection of serum ferritin and N-terminal pro-brain natriuretic peptide in the assessment of Kawasaki disease in children over 1 year of age.Italian journal of pediatrics · 2025Article
- Diagnostic Value ofPediatric cardiology · 2025Article
- Establishment and validation of a predictive model for coronary artery lesions in children with KDSS.Italian journal of pediatrics · 2025Article
- Clinical significance of caspase-1 in coronary artery lesions in Kawasaki disease and its mechanism of action on vascular smooth muscle cells.Postepy dermatologii i alergologii · 2025Article
- Vascular function and arterial stiffness in multisystem inflammatory syndrome in children with Covid-19.ARYA atherosclerosis · 2025Article
- A Nomogram Model for Predicting Recurrent Coronary Thrombosis in Kawasaki Disease Patients.Journal of inflammation research · 2025Article
- Combination of CRP and miRNA signature as a potential diagnostic strategy for Kawasaki disease.Frontiers in pediatrics · 2025Article
- Cardiac Arrest During Exertion as a Presentation of Undiagnosed Kawasaki Disease: A Case Report.Journal of clinical medicine · 2024Article
- Statin suppresses the development of excessive intimal proliferation in a Kawasaki disease mouse model.Physiological reports · 2024Article
- Expression of Oxidative Stress and Inflammatory Indicators for Coronary Artery Disease in Kawasaki Disease.Mediterranean journal of hematology and infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kawasaki disease (KD), first reported as an acute febrile mucocutaneous lymph node syndrome, is a self-limiting vasculitis of unknown etiology. The most important aspect of KD is the prevention of coronary artery lesion (CAL) because myocardial ischemia or infarction due to CAL might be lethal. In addition to the CAL, patients with KD develop systemic vasculitis, which indicates the presence of vascular endothelial damage. Studies assessing pulse wave velocity or percentage change in flow-mediated dilatation have shown that aortic stiffness is increased in patients with KD history. In contrast, the cardio-ankle vascular index, a novel parameter not affected by blood pressure, has not demonstrated increased aortic stiffness in patients with KD. Although many studies using various parameters have suggested a risk of atherosclerosis in patients with a history of KD, a few others have reported no significant differences between KD patients and controls. Therefore, it will be necessary to thoroughly understand the characteristics of each parameter, before evaluating the results of those studies, to understand systemic vascular dysfunction in these populations, and to manage their vascular health. Although it is controversial whether the risk of atherosclerosis in patients with KD is higher, those with CAL are thought to be at a high risk of atherosclerosis. Therefore, appropriate treatment to prevent CAL in the acute phase and subsequent regular follow-up is important. Here, we review the pathology, risk, and management of vascular disorders, especially systemic vascular disorders, in patients with KD history.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.